Send to

Choose Destination
Cancer J. 2013 Nov-Dec;19(6):511-6. doi: 10.1097/PPO.0000000000000007.

Dendritic cells, inflammation, and breast cancer.

Author information

From the *Ralph M. Steinmann Center for Cancer Vaccines, Baylor Institute for Immunology Research, Baylor Research Institute, Dallas, TX; †Department of Oncological Sciences, Icahn School of Medicine at Mount Sinai, New York, NY; ‡Department of Cell and Developmental Biology, Knight Cancer Institute, Oregon Health and Science University, Portland, OR; and §Baylor Sammons Cancer Center, Texas Oncology, US Oncology, Dallas, TX.


Solid tumors are well known for their genomic heterogeneity. Although some aspects of this derive from so-called driver mutations, it is now clear that tumor cells possess a seemingly limitless capacity to evade cell death pathway activation, maintain essential survival programming, and initiate resistance networks that block efficacy of cytotoxic and targeted therapy. Given this amazing survival capability, how then to design approaches for effective eradication of malignant cells? Also present within all solid tumors is a diverse assemblage of genomically stable immune cell types. Whereas some of these possess documented activities that foster tumor progression, others possess inherent activities that when favored lead to rapid tumor cell elimination. This review focuses on aspects of dendritic cell biology in solid tumors, especially breast cancers, which point to dendritic cells as a tractable tool to exploit for immune-based therapies.

[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Wolters Kluwer Icon for PubMed Central
Loading ...
Support Center